MeSH tree: N05.715.360.575.575
New research appearing in the Journal of the National Comprehensive Cancer Network found that incorporating information from prostate-specific membrane antigen (PSMA) PET/CT scans may be able to predict progression-free survival ...
Feb 9, 2026
0
15
Researchers at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy have released updated consensus guidelines and an associated reproducibility study to standardize how pathologists ...
Feb 4, 2026
0
7
For patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer, the addition of palbociclib to maintenance anti-HER2 and endocrine therapies leads to improved ...
Feb 2, 2026
0
6
Patients with advanced lung cancer who received immunochemotherapy before 15:00 (3 p.m.) had a more delayed disease progression than patients receiving treatment later in the day. The findings, published as part of a randomized ...
Feb 2, 2026
0
39
A large multinational clinical trial has found that giving health care providers access to European Organization for Research and Treatment of Cancer (EORTC) patient-reported outcome (PRO) data significantly improves the ...
Jan 27, 2026
0
8
The results of a pilot study suggest that long-term exposure to higher pollen levels leads to worse symptoms and quality of life for patients with chronic rhinosinusitis. For the 103 patients studied, levels of ragweed pollen ...
Jan 26, 2026
0
7
For patients with previously untreated, programmed death ligand 1 (PD-L1)-positive, locally advanced unresectable or metastatic triple-negative breast cancer (TNBC), sacituzumab govitecan plus pembrolizumab yields significantly ...
Jan 22, 2026
0
14
The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after they received neoadjuvant treatment and surgery predicted worse outcomes than in ...
Jan 14, 2026
0
11
Teens with advanced-stage Hodgkin lymphoma survive longer without their disease getting worse when they receive the immunotherapy nivolumab (Opdivo) instead of the immunotherapy brentuximab vedotin (brand name Adcetris) along ...
Jan 13, 2026
0
12
For patients with human epidermal growth factor receptor 2-positive (HER2-positive) metastatic or locally advanced unresected gastroesophageal adenocarcinoma (mGEA), zanidatamab and chemotherapy, with or without tislelizumab, ...
Jan 12, 2026
0
8
